Objectives To evaluate the effect of adding a 10-week treatment of adalimumab to a standardised
treatment with corticosteroids on the ability to taper more rapidly corticosteroid doses …

Objective Earlier studies of eosinophilic granulomatosis with polyangiitis (Churg‐Strauss) (EGPA),
with limited patient numbers and followup durations, demonstrated that clinical …

Background The combination of cyclophosphamide and glucocorticoids leads to remission
in most patients with antineutrophil cytoplasm antibody (ANCA)–associated vasculitides. …

Objective To compare individually tailored, based on trimestrial biological parameter
monitoring, to fixed-schedule rituximab reinfusion for remission maintenance of antineutrophil …

Importance Idiopathic inflammatory myopathies are heterogeneous in their pathophysiologic
features and prognosis. The emergence of myositis-specific autoantibodies suggests that …

Objective Relapses of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis are
important events that can cause organ dysfunction and reduce quality of life. Understanding …

Background: Biannual rituximab infusions over 18 months effectively maintain remission
after a “standard” remission induction regimen for patients with antineutrophil cytoplasmic …

Objective Hypocomplementemic urticarial vasculitis (HUV) is an uncommon vasculitis of
unknown etiology that is rarely described in the literature. We undertook this study to analyze …

Importance Older patients are underrepresented in studies of rituximab for the treatment of
antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. Little is known about …

Objective Data on adult IgA vasculitis (Henoch‐Schönlein) (IgAV) are scarce. This survey
was designed to better define the clinical spectrum of IgAV and efficacy of treatments in a …